ViscoGel® has been shown to induce a faster and stronger immune response than aluminum hydroxide in pre-clinical models. The effective antigen presentation and enhanced immune response will create opportunities for improved vaccines. The ongoing program in prophylactic vaccination with HiB-antigen targets clinical Proof-of-Concept in 2012. Studies to investigate therapeutic vaccination will also be performed.
Other potential applications
Pre-clinical studies indicate that ViscoGel® has potential as a drug delivery system that will enhance effectiveness of drugs where a targeted delivery is beneficial e.g. in oncology. Development is ongoing and opportunities will be explored in this as well as other areas.
Viscogel AB - Gunnar Asplunds Allé 32, Hus D, 171 63 Solna, Sweden - firstname.lastname@example.org
Research and Development - Viscosan & ViscoGel, medical chitosans for a new class of adjuvants and vaccine carriers.